Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographics and clinical characteristicsa

From: Tumor necrosis factor α release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients

Disease Sex (n) Race (n) Mean age, years
(range)
Mean CLASI or CDASI score Medications (patients, n)
DLE (n = 21) Females, 16
Males, 5
AA, 12
White, 8
Hispanic, 1
45.0 (23 to 64) 8 Antimalarials, 18
Methotrexate, 2
Immunosuppressants, 5
Corticosteroids, 3
Dapsone, 1
Thalidomide, 1
SCLE (n = 10) Females, 7
Males, 3
White, 9
Asian, 1
47.1 (20 to 64) 9.5 Antimalarials, 7
Immunosuppressants, 2
Corticosteroids, 2
Thalidomide, 4
TLE (n = 10) Females, 8
Males, 2
AA, 1
White, 9
42.9 (25 to 57) 10.1 Antimalarials, 10
Methotrexate, 1
DM (n = 18) Females, 15
Males, 3
AA, 1
White, 16
Asian, 1
49 (21 to 75) 14.7 Antimalarials, 10
Methotrexate, 6
Immunosuppressants, 6
Corticosteroids, 9
controls (n = 18) Females, 10
Males, 8
AA, 4
White, 12
Asian, 2
31.2 (26 to 57) N/A N/A
  1. aAA = African American; CDASI = Cutaneous Dermatomyositis Area and Severity Index; CLASI = Cutaneous Lupus Erythematosus Disease Area and Severity Index; DLE = discoid lupus erythematosus; DM = dermatomyositis; N/A = not applicable; SCLE = subacute cutaneous lupus erythematosus; TLE = tumid lupus erythematosus.